Cytogenetic study of tuberculosis patients before and after tuberculostatic drug treatment

Mutat Res. 1995 Apr;334(2):175-83. doi: 10.1016/0165-1161(95)90009-8.

Abstract

Cytogenetic analyses were carried out in lymphocytes of 15 untreated tuberculosis (tb) patients and 15 other tb patients who had received combined tuberculostatic chemotherapy HRZ (isoniazid+rifampicin+pyrazinamide) for 2 months. The frequency of chromosomal aberrations and sister-chromatid exchanges (SCEs) did not show any statistically significant differences in the patients before treatment and after exposure to combined HRZ therapy as compared to controls (p > 0.05). However, we observed that the mitotic index was significantly decreased in both groups (p < 0.05). Based on the results of the present study, we believe there is no indication for a chromosome damaging effect of HRZ and their metabolites in human lymphocytes in vivo after treatment of tuberculosis patients with optimum doses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antitubercular Agents / adverse effects*
  • Cell Division / drug effects
  • Chromosome Aberrations
  • Drug Combinations
  • Female
  • Humans
  • Isoniazid / administration & dosage
  • Isoniazid / adverse effects*
  • Lymphocytes / drug effects
  • Male
  • Middle Aged
  • Mitotic Index
  • Mutagens*
  • Pyrazinamide / administration & dosage
  • Pyrazinamide / adverse effects*
  • Rifampin / administration & dosage
  • Rifampin / adverse effects*
  • Sister Chromatid Exchange
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / pathology
  • Tuberculosis, Pulmonary / physiopathology

Substances

  • Antitubercular Agents
  • Drug Combinations
  • Mutagens
  • isoniazid, pyrazinamide, rifampin drug combination
  • Pyrazinamide
  • Isoniazid
  • Rifampin